Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Assets (2020 - 2026)

GeneDx Holdings has reported Assets over the past 7 years, most recently at $506.3 million for Q1 2026.

  • Quarterly Assets rose 13.41% to $506.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $506.3 million through Mar 2026, up 13.41% year-over-year, with the annual reading at $523.7 million for FY2025, 24.88% up from the prior year.
  • Assets was $506.3 million for Q1 2026 at GeneDx Holdings, down from $523.7 million in the prior quarter.
  • Over five years, Assets peaked at $933.3 million in Q2 2022 and troughed at $389.1 million in Q2 2024.
  • The 5-year median for Assets is $476.4 million (2023), against an average of $510.3 million.
  • Year-over-year, Assets soared 431.68% in 2022 and then crashed 49.66% in 2023.
  • A 5-year view of Assets shows it stood at $490.9 million in 2022, then dropped by 14.7% to $418.8 million in 2023, then grew by 0.15% to $419.4 million in 2024, then increased by 24.88% to $523.7 million in 2025, then decreased by 3.32% to $506.3 million in 2026.
  • Per Business Quant, the three most recent readings for WGS's Assets are $506.3 million (Q1 2026), $523.7 million (Q4 2025), and $493.9 million (Q3 2025).